River Road Asset Management LLC Acquires 674 Shares of AbbVie Inc. $ABBV

River Road Asset Management LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 1.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,355 shares of the company’s stock after buying an additional 674 shares during the quarter. River Road Asset Management LLC’s holdings in AbbVie were worth $8,195,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. TD Capital Management LLC boosted its position in AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA bought a new position in AbbVie in the 2nd quarter valued at approximately $25,000. Spurstone Advisory Services LLC bought a new stake in AbbVie during the 2nd quarter worth approximately $28,000. Financial Gravity Companies Inc. acquired a new position in AbbVie in the 2nd quarter valued at approximately $36,000. Finally, Bear Mountain Capital Inc. raised its stake in shares of AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after acquiring an additional 173 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ABBV shares. JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Hsbc Global Res lowered AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research note on Tuesday, November 4th. Finally, Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $241.85.

AbbVie Trading Down 1.3%

NYSE ABBV opened at $224.82 on Tuesday. The stock has a market capitalization of $397.34 billion, a P/E ratio of 107.06, a P/E/G ratio of 1.42 and a beta of 0.50. The business has a 50 day simple moving average of $227.74 and a 200 day simple moving average of $207.31. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the prior year, the business earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 524.24%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.